Use of modified cells for the treatment of multiple sclerosis

Patent metadata

Field	Value
Publication number	US-9260692-B2
Application number	US-201414218378-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Oct 31, 2007
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.

First claim

The invention claimed is:

1. A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell erythrocyte that is chemically coupled to at least six peptides selected from the group consisting of: MBP 13-32 (SEQ ID NO:1), MBP 83-99 (SEQ ID NO:2), MBP 111-129 (SEQ ID NO:3), MBP 82-98 (SEQ ID NO:8), MBP 82-99 (SEQ ID NO:9), MBP 82-106 (SEQ ID NO:10), MBP 87-106 (SEQ ID NO:11), MBP 131-155 (SEQ ID NO:12), MBP 146-170 (SEQ ID NO:4), PLP 41-58 (SEQ ID NO:13),PLP 89-106 (SEQ ID NO:14),PLP 95-116 (SEQ ID NO:15), HCLGKWLGHPDKFVGI (SEQ ID NO:5), PLP 178-197 (SEQ ID NO:16), SKTSASIGSLCADARMYGVL (SEQ ID NO:17), MOG 1-20 (SEQ ID NO:6), MOG 11-30 (SEQ ID NO:18), MOG 21-40 (SEQ ID NO:19), MOG 35-55 (SEQ ID NO:7), and MOG 64-86 (SEQ ID NO:20), wherein MBP is myelin basic protein, PLP is proteolipid protein and MOG is myelin oligodendrocyte protein.

2. The chemically coupled cell according to claim 1 , which cell is a red blood cell (RBC).

3. The chemically coupled cell according to claim 1 , which cell is a peripheral blood mononuclear cell (PBMC).

4. The chemically coupled cell according to claim 1 , wherein the peptides are chemically coupled by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI).

5. A pharmaceutical composition comprising the chemically coupled cell according to claim 1 and a pharmaceutically acceptable excipient.

6. A medical product comprising one or more of the chemically coupled cells according to claim 1 and an anti-coagulant.

7. A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) that is chemically coupled to each peptide in a cocktail of peptides selected from the group consisting of cocktails e-h, j-kk, mm, and nn of tables 5.1-5.3.

8. The chemically coupled cell according to claim 7 , wherein one of the MBP peptides is a citrullinated MBP peptide.

9. A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) that is chemically coupled to each peptide in a cocktail of peptides selected from the group consisting of cocktails e-h, j-kk, mm, and nn of tables 5.1-5.3 with the proviso that at least one of the myelin basic protein (MBP) peptides has been replaced with the full-length MBP protein.

10. The chemically coupled cell according to claim 9 , wherein the full length MBP protein is the 18.5 kD isoform according to SEQ ID NO: 22.

11. A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) that is chemically coupled to each peptide in a cocktail of peptides selected from the group consisting of cocktails e-h, j-kk, mm, and nn with the proviso that at least one of the proteolipid protein (PLP) peptides has been replaced with the full-length PLP protein of SEQ ID NO: 21.

12. A chemically coupled cell which is a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) that is chemically coupled to each peptide in a cocktail of peptides selected from the group consisting of cocktails e-h, j-kk, mm, and nn with the proviso that at least one of the myelin oligodendrocyte glycoprotein (MOG) peptides has been replaced with the full-length MOG protein according to SEQ ID NO: 23.

13. A method for the treatment of an autoimmune inflammatory disease in a subject in need thereof, comprising administering into said subject a therapeutically effective amount of said chemically coupled cells according to claim 1 .

14. The method according to claim 13 , wherein the autoimmune inflammatory disease is multiple sclerosis (MS).

15. The method according to claim 13 , wherein the chemically coupled cells are allogenic cells relative to said subject.

16. The method according to claim 13 , wherein the chemically coupled cells are autologous cells relative to said subject.

17. A process for the manufacture of a chemically coupled cell according to claim 1 , comprising
(a) contacting in the presence of a coupling agent (i) a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) with (ii) at least six peptides selected from the group consisting of: MBP 13-32 (SEQ ID NO:1), MBP 83-99 (SEQ ID NO:2), MBP 111-129 (SEQ ID NO:3), MBP 82-98 (SEQ ID NO:8), MBP 82-99 (SEQ ID NO:9), MBP 82-106 (SEQ ID NO:10), MBP 87-106 (SEQ ID NO:11), MBP 131-155 (SEQ ID NO:12), MBP 146-170 (SEQ ID NO:4), PLP 41-58 (SEQ ID NO:13), PLP 89-106 (SEQ ID NO:14), PLP 95-116 (SEQ ID NO:15), HCLGKWLGHPDKFVGI (SEQ ID NO:5), PLP 178-197 (SEQ ID NO:16), SKTSASIGSLCADARMYGVL (SEQ ID NO:17), MOG 1-20 (SEQ ID NO:6), MOG 11-30 (SEQ ID NO:18), MOG 21-40 (SEQ ID NO:19), MOG 35-55 (SEQ ID NO:7), and MOG 64-86 (SEQ ID NO:20), wherein MBP is myelin basic protein, PLP is proteolipid protein and MOG is myelin oligodendrocyte protein and
(b) carrying out a chemical reaction to couple the cell to each of the at least six peptides, thereby forming said chemically coupled cell.

18. The process according to claim 17 , wherein the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI).

19. A process for the manufacture of a chemically coupled cell according to claim 7 , comprising
(a) contacting in the presence of a coupling agent (i) a peripheral blood mononuclear cell (PBMC) or a red blood cell (RBC) with (ii) at least one of said cocktail of peptides e-h, j-kk, mm, or nn of tables 5.1-5.3, and
(b) carrying out a chemical reaction to couple the cell to each of the peptides in the cocktail, thereby forming said chemically coupled cell.

Assignees

• Univ Zuerich

Inventors

• Martin Roland
• Lutterotti Andreas

Classifications

• A61K40/414

  Nervous system antigens · CPC title

• A61K40/10

  characterised by the cell type used · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• C12N5/0634

  Cells from the blood or the immune system · CPC title